Despite reports that Pfizer is now the front-runner to snap up cancer biotech Medivation, its original suitor Sanofi is confident that its low ball $9.3 billion offer will be accepted after filing under the Hart-Scott-Rodino Antitrust Improvements Act.
This move, which happens when a company believes it is about to subsume another company, shows Sanofi’s bullishness in getting the deal done–despite the fact that it was roundly rejected by Medivation just weeks’ ago and comes amid swirling rumors that it has opened talks with Pfizer.
Sanofi has in the past week hinted at both potentially extending its offer–but also going hostile if the Xtandi producer’s board doesn’t play ball.
In a brief statement, the French drugmaker–which is looking to beef up its relatively weak and until recently half abandoned oncology pipeline–said: “As announced on April 28, 2016, Sanofi proposed to acquire Medivation for $52.50 per share, representing an all-cash transaction valued at approximately $9.3 billion”–indicating it is not yet willing to budge on price.
Analysts have said the biotech could fetch as much as $70 a share, with Novartis, AstraZeneca and Amgen also all said to be circling.
By Ben Adams
Source: Fierce Biotech
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
